Efficacy of HX008 in high microsatellite instability/mismatch repair-defificient (MSI-H/dMMR) solid tumors: Results from a multicenter phase II open-label study
机构：[1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[2]Henan Cancer Hospital, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China河南省肿瘤医院[3]Hunan Cancer Hospital, Hunan, China[4]Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xian, China[5]Tianjin People's Hospital, Tianjin, China[6]Department of Oncology, The First Affiliated Hospital of USTC West District& Anhui Provicial Cancer Hospital, Hefei, China[7]Guangxi Medical University Cancer Hospital, Nanning, China[8]Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China[9]Hubei Cancer Hospital, Wuhan, China[10]Jiangsu Province Hospital, Jiangsu, China江苏省人民医院[11]Medical Oncology, The First Hospital of China Medical University, Shenyang, China[12]The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China浙江大学医学院附属第一医院[13]Department of Medical Oncology, Shandong Cancer Hospital, Jinan, China[14]The Second Affiliated Hospital of Soochow University, Suzhou, China苏州大学附属第二医院[15]Liaoning Cancer Hospital, Shenyang, China[16]The First Affiliated Hospital of Xinxiang Medical College, Xinxiang, China[17]Peking University Shenzhen Hospital, Shenzhen, China北京大学深圳医院深圳医学信息中心[18]Fudan University Shanghai Cancer Center, Shanghai, China[19]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院
第一作者机构：[1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China[2]Henan Cancer Hospital, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China[3]Hunan Cancer Hospital, Hunan, China[4]Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xian, China[5]Tianjin People's Hospital, Tianjin, China[6]Department of Oncology, The First Affiliated Hospital of USTC West District& Anhui Provicial Cancer Hospital, Hefei, China[7]Guangxi Medical University Cancer Hospital, Nanning, China[8]Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China[9]Hubei Cancer Hospital, Wuhan, China[10]Jiangsu Province Hospital, Jiangsu, China[11]Medical Oncology, The First Hospital of China Medical University, Shenyang, China[12]The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China[13]Department of Medical Oncology, Shandong Cancer Hospital, Jinan, China[14]The Second Affiliated Hospital of Soochow University, Suzhou, China[15]Liaoning Cancer Hospital, Shenyang, China[16]The First Affiliated Hospital of Xinxiang Medical College, Xinxiang, China[17]Peking University Shenzhen Hospital, Shenzhen, China[18]Fudan University Shanghai Cancer Center, Shanghai, China
推荐引用方式(GB/T 7714)：
Huang Jing,Song Yan,Luo Suxia,et al.Efficacy of HX008 in high microsatellite instability/mismatch repair-defificient (MSI-H/dMMR) solid tumors: Results from a multicenter phase II open-label study[J].JOURNAL OF CLINICAL ONCOLOGY.2021,39(15):doi:10.1200/JCO.2021.39.15_suppl.2572.
APA：
Huang, Jing,Song, Yan,Luo, Suxia,Yin, Xianli,Li, Enxiao...&Li, Shengmian.(2021).Efficacy of HX008 in high microsatellite instability/mismatch repair-defificient (MSI-H/dMMR) solid tumors: Results from a multicenter phase II open-label study.JOURNAL OF CLINICAL ONCOLOGY,39,(15)
MLA：
Huang, Jing,et al."Efficacy of HX008 in high microsatellite instability/mismatch repair-defificient (MSI-H/dMMR) solid tumors: Results from a multicenter phase II open-label study".JOURNAL OF CLINICAL ONCOLOGY 39..15(2021)
医学